Amalgamated Bank’s Biodesix BDSX Stock Holding History

Amalgamated Bank’s Portfolio BDSX Stock Details BDSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-105	Closed	-$4K	–	3045
2022 Q1	$4K	Buy	+105	New	+$6.86K	﹤0.01%	3033

Other funds holding BDSX

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Amalgamated Bank's BDSX Position: Q2 2022 in Review

Amalgamated Bank sold out of Biodesix (BDSX) in Q2 2022, closing a stake of 105 shares — an estimated $4K sold.

Amalgamated Bank first reported a position in BDSX in Q1 2022 and held it in 1 quarter. The position peaked at $4K in Q1 2022. 36 funds tracked by Wall St. Rank hold BDSX as of Q2 2022.

Amalgamated Bank reported no remaining Biodesix position as of Q2 2022 after selling out during the quarter.
Amalgamated Bank sold 105 Biodesix shares in Q2 2022, an estimated $4K.
Amalgamated Bank first reported a position in Biodesix in Q1 2022 and held it in 1 quarter.
Amalgamated Bank's Biodesix position peaked at $4K in Q1 2022.
36 funds tracked by Wall St. Rank held Biodesix as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.